[go: up one dir, main page]

MXPA03000765A - Polypeptide delivery ii-2. - Google Patents

Polypeptide delivery ii-2.

Info

Publication number
MXPA03000765A
MXPA03000765A MXPA03000765A MXPA03000765A MXPA03000765A MX PA03000765 A MXPA03000765 A MX PA03000765A MX PA03000765 A MXPA03000765 A MX PA03000765A MX PA03000765 A MXPA03000765 A MX PA03000765A MX PA03000765 A MXPA03000765 A MX PA03000765A
Authority
MX
Mexico
Prior art keywords
red blood
blood cell
polypeptide delivery
agent
mts
Prior art date
Application number
MXPA03000765A
Other languages
Spanish (es)
Inventor
Roger Craig
Original Assignee
Gendel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/002848 external-priority patent/WO2001007011A1/en
Priority claimed from PCT/GB2000/003056 external-priority patent/WO2001058431A1/en
Priority claimed from US09/785,802 external-priority patent/US20020151004A1/en
Application filed by Gendel Ltd filed Critical Gendel Ltd
Publication of MXPA03000765A publication Critical patent/MXPA03000765A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

We describe a method of preparing a red blood cell vehicle suitable for delivering an agent to a target site in a vertebrate, the method comprising the steps of: (a) providing a red blood cell; and (b) loading the red blood cell with an agent-MTS conjugate.
MXPA03000765A 2000-07-24 2001-07-24 Polypeptide delivery ii-2. MXPA03000765A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2000/002848 WO2001007011A1 (en) 1999-07-23 2000-07-24 Method for releasing an agent from a red blood cell
PCT/GB2000/003056 WO2001058431A1 (en) 2000-02-08 2000-08-09 Method for loading a red blood cell with an agent
GB0100417 2001-02-01
US09/785,802 US20020151004A1 (en) 2000-07-24 2001-02-16 Delivery vehicles and methods for using the same
PCT/GB2001/003327 WO2002007752A2 (en) 2000-07-24 2001-07-24 Red blood cell as vehicle for agent-membrane translocation sequence conjugate

Publications (1)

Publication Number Publication Date
MXPA03000765A true MXPA03000765A (en) 2004-05-21

Family

ID=56290173

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000765A MXPA03000765A (en) 2000-07-24 2001-07-24 Polypeptide delivery ii-2.

Country Status (5)

Country Link
EP (1) EP1355656A2 (en)
AU (1) AU2001272670A1 (en)
CA (1) CA2412544A1 (en)
MX (1) MXPA03000765A (en)
WO (1) WO2002007752A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
CA2875618C (en) 2012-07-11 2021-04-27 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP2868326A1 (en) * 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptide inhibitors of TEAD/YAP-TAZ interaction
CA3001154C (en) 2015-10-07 2023-10-17 Sangui Bio Pty. Ltd Blood preparation and profiling
WO2017070196A1 (en) * 2015-10-21 2017-04-27 The Methodist Hospital System Cellular vectors for delivery of therapeutics
EP3393482A4 (en) * 2015-12-22 2019-08-21 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
AU2018381224A1 (en) * 2017-12-04 2020-06-11 The General Hospital Corporation Extracellular redox enzyme system to alleviate disease
WO2020159445A1 (en) 2019-01-31 2020-08-06 Agency For Science, Technology And Research Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
CA3106693A1 (en) 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
JP2022553828A (en) 2019-11-01 2022-12-26 サンガモ セラピューティクス， インコーポレイテッド Compositions and methods for genome manipulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245867B (en) * 1991-06-03 1994-10-25 Consiglio Nazionale Ricerche VACCINES USING ERYTHROCYTES AS ANTIGEN VEHICLES
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
GB9816583D0 (en) * 1998-07-31 1998-09-30 Univ Ulster Nucleic acid carrier
GB9917416D0 (en) * 1999-07-23 1999-09-22 Univ Ulster

Also Published As

Publication number Publication date
AU2001272670A1 (en) 2002-02-05
WO2002007752A3 (en) 2003-08-28
EP1355656A2 (en) 2003-10-29
WO2002007752A2 (en) 2002-01-31
CA2412544A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
MXPA03000765A (en) Polypeptide delivery ii-2.
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
WO2004052401A3 (en) Compositions and methods of delivery of pharmacological agents
NZ502358A (en) Hydrogel composition comprising a biologically active substance combined with a macromer
NZ548716A (en) Capillary moderator in an osmotic delivery system for preventing backflow into the active agent reservoir
IL144597A0 (en) Hydrogel particle formulations
IL132156A0 (en) Neoglycoproteins
GB2402345A (en) Needle with lateral aperture
NZ330145A (en) Drug delivery system, typically ring-shaped, for vaginal administration, with steroidal compounds dissolved in polymer core and with polymer skin
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
MXPA02009275A (en) Method for preparing high pressure high shear dispersions containing physiologically active ingredients.
WO1999047173A3 (en) Carrier for in vivo delivery of a therapeutic agent
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
MXPA02010801A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
CA2396152A1 (en) Osmotic device within an osmotic device
EP1375519A3 (en) Method for affecting cellular function using antibodies
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
EP0993831A3 (en) Compounds and compositions for delivering active agents
EP1235291A3 (en) Fuel cell system
TW200630106A (en) Immunotherapy of autoimmune disorders
AU2001257305A1 (en) Hematology blood control and method for preparation of same
WO2004113422A3 (en) Drug delivery device comprising an active compound and method for releasing an active compound from a drug delivery device
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.